Drugs / Valaciclovir
Valaciclovir
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02226978 | Feb → May 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00297206 | Jan 2003 → Feb 2007 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03699904 | Oct 2018 → May 2020 | Epstein-Barr virus infection, chronic obstructive pulmonary disease | Belfast Health and Social Care Trust | Terminated | No outcome recorded |
| Phase 2 | NCT02997982 | Dec 2016 → Mar 2020 | Alzheimer disease, herpes simplex infectious disease, subjective cognitive decline | Hugo Lovheim | Completed | No outcome recorded |
| Phase 2 | NCT01503918 | Jan 2012 → Jan 2014 | — | University Hospital Birmingham NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT01364792 | Apr 2011 → Aug 2015 | schizophrenia | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT00652184 | Mar 2008 → Jun 2009 | herpes zoster, postherpetic neuralgia | aRigen Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05902208 | Feb 2024 → May 2026 | chronic periodontitis | Centre Hospitalier Universitaire de Nice | Unknown | No outcome recorded |
| Phase 3 | NCT01959841 | Aug 2013 → Jul 2015 | herpes zoster | Maruho Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01602562 | May 2012 → May 2013 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00169416 | Mar → Aug 2005 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00001649 | Aug 1997 → Aug 2003 | genital herpes | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT00343278 | Jul → Aug 2005 | viral infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00116844 | Mar 2005 → Jan 2006 | Herpesviridae infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00158860 | Jun 2004 → Jul 2006 | genital herpes simplex type 2 infectious disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00510263 | May 2001 → Sep 2007 | Bell's palsy | Uppsala University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07346144 Background | Apr 2026 → Mar 2030 expected | glioblastoma | Trogenix ltd | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04165122 Comparator | Nov 2019 → Aug 2021 | genital herpes | Heidelberg ImmunoTherapeutics GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01633476 Comparator | Jul 2013 → Feb 2016 | anti-neutrophil cytoplasmic antibody-associated vasculitis, cytomegalovirus infection | Professor Lorraine Harper | Unknown | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-05-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Valtrex® tevapharm.com ↗ |
| 2007-10-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Generic Valtrex® tevapharm.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Valaciclovir | “Valaciclovir, a antiviral treatment will be added to the conventional non-surgical treatment of generalized periodontitis. One gram per day will be administered” NCT05902208 ↗ |
| Known as | VACV | “To evaluate the efficacy and safety of ASP2151 (200 mg and 400 mg) in comparison with valaciclovir (VACV) 3000 mg in patients with herpes zoster.” NCT01959841 ↗2“Valaciclovir (VACV), the L-valyl ester prodrug of aciclovir (ACV), is extensively converted to ACV and L-valine after oral administration.” NCT00343278 ↗ “256U87 (VACV: valaciclovir)” NCT01602562 ↗ |
| Known as | VAL | “Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)” NCT02226978 ↗ |
| Known as | valacyclovir hydrochloride | “with valacyclovir hydrochloride (n = 34) or low-dose valganciclovir hydrochloride” PMID 28437539 ↗ Jun 2017 |
| Known as | Valtrex | “Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF” NCT00297206 ↗ |
| Action | Inhibit | “Valaciclovir prevents the herpes virus from multiplying” NCT00001649 ↗ |
| Route | Oral | “The source partner will be randomly assigned to take either a 500-mg tablet of valaciclovir or placebo (a pill with no active ingredient) daily for 8 months.” NCT00001649 ↗ |